Back to Search Start Over

68 Ga-FAPI04 Versus 68 Ga-DOTATATE PET/CT in a Patient With Multiple Meningioma.

Authors :
Denizmen D
Isik EG
Buyukkaya F
Kuyumcu S
Source :
Clinical nuclear medicine [Clin Nucl Med] 2023 May 01; Vol. 48 (5), pp. e244-e245. Date of Electronic Publication: 2023 Mar 06.
Publication Year :
2023

Abstract

Abstract: We present the 68 Ga-DOTATATE and 68 Ga-FAPI (fibroblast activation protein inhibitor) PET/CT findings of a 61-year-old man diagnosed with atypical World Health Organization grade II multiple meningiomas. The patient has been stable for 2 years following multiple surgeries and external radiotherapy because of recurring disease until he recently described frequent headaches, and a follow-up examination confirmed new meningioma lesions on MRI. However, the patient was inoperable and was referred for 68 Ga-DOTATATE PET/CT to determine eligibility for salvage peptide receptor radionuclide therapy. He also underwent fibroblast activation protein-targeted imaging using 68 Ga-FAPI04 PET/CT, which revealed heterogeneous, low to mild fibroblast activation protein expression across multiple meningioma lesions.<br />Competing Interests: Conflicts of interest and sources of funding: none declared.<br /> (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Details

Language :
English
ISSN :
1536-0229
Volume :
48
Issue :
5
Database :
MEDLINE
Journal :
Clinical nuclear medicine
Publication Type :
Academic Journal
Accession number :
36881633
Full Text :
https://doi.org/10.1097/RLU.0000000000004617